Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up

International Urology and Nephrology

Volumn 39, Issue 1, 2007, Pages 317-319

  Sheashaa, Hussein A ^a   Bakr, Mohamed A ^a   Fouda, Mohamed Ashraf ^a   El dahshan, Khalid F ^a   Ismail, Amany M ^a   Sobh, Mohamed A ^a   Ghoneim, Mohamed A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Daclizumab; Induction therapy; Kidney transplantation; Mycopheolate mofetil

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; MALE; NEPHROTOXICITY; RECIPIENT;

ACTUARIAL ANALYSIS; ADULT; ANTIBODIES, MONOCLONAL; DEMOGRAPHY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MYCOPHENOLIC ACID; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE DONORS;

EID: 34248224646     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-006-9091-8     Document Type: Article

References (9)

1. Nashan B, Light S, Hardie IR, Lin A, Johnson RJ (1999) Reduction of acute renal allograft rejection by daclizumab. Transplantation 67:110-115
2. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP (1997) Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350:1193-1198
3. Kahan BD, Rajagopalan PR, Hall M (1999) Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 67:276-284
4. Kandus A, Grego K, Bren AF (2005) Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients. Ther Apher Dial 9(3):262-264
5. Danovitch GM (2005) Immunosuppressive medications and protocols for kidney transplantation. In: Danovitch GM (ed) Handbook of kidney transplantation, 4th edn. Lippincott and Wilkins, Boston, pp 72-133
6. Morales JM (2005) Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Kidney Int Suppl 99:S124-S130
7. Racusen L, Solez K, Colvin R, Bonsib S et al (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int 55:713-723
8. Vincenti F, Kirkman R, Light S et al (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338:161
9. Morris JA, Hanson JE, Steffen BJ, Chu AH, Chi-Burris KS, Gotz VP, Gordon RD (2005) Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transplant 19(3):340-345